Lilly’s Zepbound Beats Novo’s Wegovy in Head-to-Head Trial
Eli Lilly’s weight-loss drug Zepbound has emerged as the winner in its first head-to-head trial, with users losing 20% of their body weight over a 72-week period. In contrast, those who received Wegovy shed just 14%. The study’s findings reinforce earlier trials and suggest that Zepbound has a stronger impact on weight loss, offering new … Read more